210 related articles for article (PubMed ID: 29026104)
1. CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.
Ishii T; Okai T; Iwatani-Yoshihara M; Mochizuki M; Unno S; Kuno M; Yoshikawa M; Shibata S; Nakakariya M; Yogo T; Kawamoto T
Sci Rep; 2017 Oct; 7(1):13000. PubMed ID: 29026104
[TBL] [Abstract][Full Text] [Related]
2. Quantitative target engagement of RIPK1 in human whole blood via the cellular thermal shift assay for potential pre-clinical and clinical applications.
Patel S; Karlsson M; Klahn JT; Gambino F; Costa H; McGuire KA; Baumgartner CK; Williams J; Sandoz S; Kath JE
SLAS Discov; 2024 Mar; 29(2):100135. PubMed ID: 38101572
[TBL] [Abstract][Full Text] [Related]
3. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
[TBL] [Abstract][Full Text] [Related]
4. Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor.
Delanghe T; Huyghe J; Lee S; Priem D; Van Coillie S; Gilbert B; Choi SM; Vandenabeele P; Degterev A; Cuny GD; Dondelinger Y; Bertrand MJM
Cell Death Dis; 2021 Jul; 12(7):699. PubMed ID: 34262020
[TBL] [Abstract][Full Text] [Related]
5. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.
Fauster A; Rebsamen M; Huber KV; Bigenzahn JW; Stukalov A; Lardeau CH; Scorzoni S; Bruckner M; Gridling M; Parapatics K; Colinge J; Bennett KL; Kubicek S; Krautwald S; Linkermann A; Superti-Furga G
Cell Death Dis; 2015 May; 6(5):e1767. PubMed ID: 25996294
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity.
Li Z; Hao Y; Yang C; Yang Q; Wu S; Ma H; Tian S; Lu H; Wang J; Yang T; He S; Zhang X
Eur J Med Chem; 2022 Jan; 228():114036. PubMed ID: 34906762
[TBL] [Abstract][Full Text] [Related]
7. Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.
Le Cann F; Delehouzé C; Leverrier-Penna S; Filliol A; Comte A; Delalande O; Desban N; Baratte B; Gallais I; Piquet-Pellorce C; Faurez F; Bonnet M; Mettey Y; Goekjian P; Samson M; Vandenabeele P; Bach S; Dimanche-Boitrel MT
FEBS J; 2017 Sep; 284(18):3050-3068. PubMed ID: 28715128
[TBL] [Abstract][Full Text] [Related]
8. The Cellular Thermal Shift Assay: A Novel Biophysical Assay for In Situ Drug Target Engagement and Mechanistic Biomarker Studies.
Martinez Molina D; Nordlund P
Annu Rev Pharmacol Toxicol; 2016; 56():141-61. PubMed ID: 26566155
[TBL] [Abstract][Full Text] [Related]
9. Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues.
Finger JN; Brusq JM; Campobasso N; Cook MN; Deutsch J; Haag H; Harris PA; Jenkins EL; Joglekar D; Lich JD; Maguire S; Nagilla R; Rivera EJ; Sun H; Votta BJ; Bertin J; Gough PJ
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226625
[TBL] [Abstract][Full Text] [Related]
10. The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
Qin X; Hu L; Shi SN; Chen X; Zhuang C; Zhang W; Jitkaew S; Pang X; Yu J; Tan YX; Wang HY; Cai Z
Biochem Pharmacol; 2020 Jul; 177():113947. PubMed ID: 32247850
[TBL] [Abstract][Full Text] [Related]
11. Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
Li Y; Xiong Y; Zhang G; Zhang L; Yang W; Yang J; Huang L; Qiao Z; Miao Z; Lin G; Sun Q; Niu T; Chen L; Niu D; Li L; Yang S
J Med Chem; 2018 Dec; 61(24):11398-11414. PubMed ID: 30480444
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
[TBL] [Abstract][Full Text] [Related]
13. Genetic Inhibition of Receptor Interacting Protein Kinase-1 Reduces Cell Death and Improves Functional Outcome After Intracerebral Hemorrhage in Mice.
Lule S; Wu L; McAllister LM; Edmiston WJ; Chung JY; Levy E; Zheng Y; Gough PJ; Bertin J; Degterev A; Lo EH; Whalen MJ
Stroke; 2017 Sep; 48(9):2549-2556. PubMed ID: 28765287
[TBL] [Abstract][Full Text] [Related]
14.
Zhang H; Xu L; Qin X; Chen X; Cong H; Hu L; Chen L; Miao Z; Zhang W; Cai Z; Zhuang C
J Med Chem; 2019 Jul; 62(14):6665-6681. PubMed ID: 31095385
[TBL] [Abstract][Full Text] [Related]
15. RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress.
Wang JN; Liu MM; Wang F; Wei B; Yang Q; Cai YT; Chen X; Liu XQ; Jiang L; Li C; Hu XW; Yu JT; Ma TT; Jin J; Wu YG; Li J; Meng XM
Clin Sci (Lond); 2019 Jul; 133(14):1609-1627. PubMed ID: 31315969
[TBL] [Abstract][Full Text] [Related]
16. MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death.
Dondelinger Y; Delanghe T; Rojas-Rivera D; Priem D; Delvaeye T; Bruggeman I; Van Herreweghe F; Vandenabeele P; Bertrand MJM
Nat Cell Biol; 2017 Oct; 19(10):1237-1247. PubMed ID: 28920952
[TBL] [Abstract][Full Text] [Related]
17. Visualization of Receptor-Interacting Protein Kinase 1 (RIPK1) by Brain Imaging with Positron Emission Tomography.
Lan Y; Bai P; Liu Y; Afshar S; Striar R; Rattray AK; Meyer TN; Langan AG; Posner AM; Shen S; Tanzi RE; Zhang C; Wang C
J Med Chem; 2021 Oct; 64(20):15420-15428. PubMed ID: 34652135
[TBL] [Abstract][Full Text] [Related]
18. Cell Density Affects the Detection of Chk1 Target Engagement by the Selective Inhibitor V158411.
Geneste CC; Massey AJ
SLAS Discov; 2018 Feb; 23(2):144-153. PubMed ID: 29048945
[TBL] [Abstract][Full Text] [Related]
19. Ring closure strategy leads to potent RIPK3 inhibitors.
Wu S; Xu C; Xia K; Lin Y; Tian S; Ma H; Ji Y; Zhu F; He S; Zhang X
Eur J Med Chem; 2021 May; 217():113327. PubMed ID: 33730678
[TBL] [Abstract][Full Text] [Related]
20. Potent Inhibition of Necroptosis by Simultaneously Targeting Multiple Effectors of the Pathway.
Pierotti CL; Tanzer MC; Jacobsen AV; Hildebrand JM; Garnier JM; Sharma P; Lucet IS; Cowan AD; Kersten WJA; Luo MX; Liang LY; Fitzgibbon C; Garnish SE; Hempel A; Nachbur U; Huang DCS; Czabotar PE; Silke J; van Delft MF; Murphy JM; Lessene G
ACS Chem Biol; 2020 Oct; 15(10):2702-2713. PubMed ID: 32902249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
